SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-247354"
 

Search: id:"swepub:oai:DiVA.org:uu-247354" > Neuroendocrine Tumo...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Modlin, Irvin M. (author)

Neuroendocrine Tumor Biomarkers : Current Status and Perspectives

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-10-02
  • S. Karger AG,2014
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-247354
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-247354URI
  • https://doi.org/10.1159/000368363DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The identification of accurate harbingers of disease status and therapeutic efficacy are critical requirements in precise diagnosis and effective management. Initially, tissue analysis was regarded as ideal but invasive strategies represent risk compared with peripheral blood sampling. Thus far, most biomarkers, whether in tissue or blood/urine, have been single analytes with varying degrees of sensitivity and specificity. Some analytes have not exhibited robust metrics or have lacked methodological rigor. Neuroendocrine disease represents an area of dire biomarker paucity since the individual biomarkers (gastrin, insulin, etc.) are not widely applicable to the diverse types of neuroendocrine neoplasia. Broad-spectrum markers such as chromogranin A have limitations in sensitivity, specificity and reproducibility. Mono-analytes cannot define the multiple variables (proliferation, metabolic activity, invasive potential, metastatic propensity) that constitute tumor growth. The restricted status of the neuroendocrine neoplasia field has resulted in a lack of comprehensive knowledge of the molecular and cellular biology of the disease, with tardy application of innovative technology. This overview examines limitations in current practice and describes contemporary viable strategies under evaluation, including the identification of novel analytes ( gene transcripts, microRNA), circulating tumor cells and metabolic imaging agents that identify disease. Novel requirements are necessary to develop biomathematical algorithms for synchronous calibration of multiple molecular markers and predictive nomograms that interface biological variables to delineate disease progress or treatment efficacy. Optimally, the application of novel techniques and amalgamations of multianalyte assessment will provide a personalized molecular disease signature extrapolative of neuroendocrine neoplasia status and likelihood of progression and predictive of therapeutic opportunity.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Öberg, KjellUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)kjellob (author)
  • Taylor, Andrew (author)
  • Drozdov, Ignat (author)
  • Bodei, Lisa (author)
  • Kidd, Mark (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Neuroendocrinology: S. Karger AG100:4, s. 265-2770028-38351423-0194

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Modlin, Irvin M.
Öberg, Kjell
Taylor, Andrew
Drozdov, Ignat
Bodei, Lisa
Kidd, Mark
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Neurosciences
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Endocrinology an ...
Articles in the publication
Neuroendocrinolo ...
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view